CRO
“Evidence-based” development
A CRO that combines scientific rigor, proprietary technology, and AI
Speed to proof, speed to market
Every week you save on your development plan means market share protected. By co-designing studies with minimal burden, digitizing every step from the e-CRF to statistical analysis, and automating SAS/R programming pipelines, we shorten the time between protocol approval and publication, ensuring your evidence reaches regulators, payers, and prescribers before your competitors’ do.
Regulatory certainty and risk-mitigated execution
A promising molecule can fail simply because of the regulatory process. Our teams have a thorough understanding of the entire regulatory landscape (EMA, FDA, ANSM, CPP, CNIL, Health Data Hub) and select the optimal framework for each study (RIPH 2 vs. 3, MR-001 to 004). The result: submissions accepted on the first try, audits passed from start to finish, and a development path free of avoidable surprises.
Real-World Impact and Patient Engagement
Clinical research no longer stops at the study site—it follows patients where they live. Thanks to hybrid e-cohorts, connected devices, and certified access to national health databases (SNDS), we capture real-world evidence while designing a patient experience that fosters engagement—from the first contact to the final questionnaire—a decisive factor in the success of long-term studies.
Aligning science, operations, and technology to turn every study into a competitive advantage
Driven by our CRO subsidiary Alsinova, we operate across the entire evidence lifecycle—from pre-clinical research to clinical trials and real-world evidence (RWE) studies—utilizing flexible collaboration models (Consulting, FSP, and Full Service).
Our teams support life sciences stakeholders in the most demanding fields, notably oncology, rare diseases, immunology, and metabolic diseases, by combining scientific expertise, access to health data, and artificial intelligence to accelerate evidence generation while guaranteeing quality, compliance, and strict adherence to timelines.
26
Countries covered
2 017
SNDS-accredited engineering firm
7
Life sciences segments covered
Study Co-design, Regulatory Strategy & Early Access
- Study co-design and data source strategy: we design low-burden studies with the patient’s voice integrated right from the protocol, providing a transparent assessment of every mobilizable data source (investigator sites, patients, connected devices, SNDS).
- Regulatory pathways and submissions: we select the optimal framework for each project (RIPH 2 vs. RIPH 3; MR-001 to 004 vs. CNIL authorization) and lead the entire preparation process, from pre-synopsis to regulatory review (CPP, ANSM, CNIL, Health Data Hub), including scientific advice and patient association involvement.
- Early and compassionate access (AAP/AAC): end-to-end management, from regulatory navigation with the FDA, EMA, and national authorities to safety and efficacy monitoring, to bring innovative treatments to patients with unmet medical needs.
Clinical Operations & Real-World Evidence (RWE) Studies
- Clinical operations and risk-based monitoring: one dedicated Site Manager per site, from selection to closure, supported by a CRM-type system. Our ARC teams in Europe and North America work on daily analytics specific to each study, which continuously identify data density discrepancies and high-risk practices.
- Real-world studies and hybrid e-cohorts: prospective e-cohorts, registries, ambispecific and retrospective designs, and hybrid protocols linked to national health databases. Our proprietary platform maintains patient engagement over many years, whereas large cohorts lose their evidence due to attrition.
- Medical writing and publishing: protocols, eCRFs, and ePROs designed by cross-functional teams of medical writers and digital experts. Documents designed to move through the regulatory review process more quickly, generate analyzable data sooner, and be converted into abstracts accepted for international conferences.
Data, Biostatistics, Safety Monitoring & AI
- Data management, biostatistics, and AI-accelerated analytics: from pre-clinical omics pipelines to CDISC-compliant databases (CDASH, SDTM, ADaM), the entire chain is secured from baseline lock to analysis. Highly automated SAS and R programming, and AI-assisted SDTM mapping.
- SNDS, EGB, and population-scale evidence: accredited study office since 2017 (RERC171027), member of the AFCROs Real World Data group and REDSIAM. The first study office in France to have led the simplified access procedure to the EGB in less than 15 days. We link National Health Insurance data to your prospective studies.
- Pharmacovigilance and regulatory affairs: a global team covering the entire product lifecycle (SDEA, case processing, etc.) and MA management across the pharma, medical device (MD), IVD, cosmetic, and food supplement segments. RegIntel, our proprietary solution, automates AE processing and compliance tracking.
Our Quotes
Our engagements
Our Research
At a time when development costs are rising and regulatory expectations are becoming more stringent, competitiveness in the life sciences hinges on a single capability: generating the right evidence faster than the market moves.
Our Articles
Five Best Practices for Implementing a Clinical Data Fabric (CDF)
A Clinical Data Framework (CDF) is a type of data architecture that enables pharmaceutical companies, medtech firms…
How digitalization improves clinical data management practice
Clinical trials generate a massive amount of data. In most cases, the challenge lies less in the volume of data to be processed than in its diversity.
Facilitate the mapping of data to the SDTM format through standardization and AI.
Our clients are mid-to-large size healthcare companies based in Europe, willing to fully embrace digital technologies.
Strasbourg University Hospitals | PRAISE, Toxicities of Immunotherapy in Oncology
PRAISE (Patient-Reported AutoImmunity Secondary to Cancer Immunotherapy) is a real-world, longitudinal, observational study conducted in collaboration with the Strasbourg University Hospitals to identify autoimmune manifestations in patients treated with immune checkpoint inhibitors. Immunotherapy has revolutionized survival in oncology, but its autoimmune toxicities remain poorly characterized in real-world settings. By collecting patient-reported data longitudinally, alongside clinical follow-up, the study is building the evidence base that clinicians need to anticipate, detect, and manage these toxicities—precisely where trial data ends and real-world practice begins.
RESILIENCE | RC-102, a clinical trial of a CE-marked oncology telemonitoring solution
RESILIENCE | RC-102, a clinical trial of a CE-marked oncology telemonitoring solution Resilience is a CE-marked digital solution designed for telemonitoring and supportive care for oncology patients, combining a platform used by healthcare professionals with a patient app. We conducted the RC-102 clinical investigation and managed its data, generating the clinical evidence needed to support a digital medical device in oncology. This demonstrates our ability to operate at the intersection of oncology, medical device regulation, and digital health—an area where few CROs have proven expertise in all three.
e-Lupus, a national e-cohort designed to streamline the care pathway for rare diseases
Within the French rare disease healthcare sector, we have built and operate the e-Lupus e-cohort dedicated to lupus patients, deployed on our patient platform, which has already been proven effective in therapeutic areas related to systemic lupus erythematosus and rheumatoid arthritis. The platform digitizes patient enrollment, follow-up, and data collection across the healthcare network, transforming a dispersed rare disease population into a structured and analyzable cohort, with the security safeguards required for this type of data.
European Hospital | AutoEvaLUP, a lupus e-cohort linked to the SNDS
The AutoEvaLUP study tracks adult patients with systemic lupus erythematosus across the dimensions that define their daily lives—fatigue, pain, anxiety, and depression—and links a prospective e-cohort to the National Health Database (SNDS). This hybrid design enriches patient and clinical data with comprehensive medical-administrative data: treatment histories, hospitalizations, and healthcare utilization—including for patients who have been lost to follow-up. Our certified access to the SNDS translates into concrete scientific value.
Strasbourg University Hospitals | COMBATT, National Observatory on Combination Targeted Therapies
COMBATT is a national registry of targeted therapies administered in combination for refractory immune-mediated inflammatory diseases—specifically, patients for whom standard sequential treatment strategies have failed and for whom no trial data exist. Operating a national registry for a refractory patient population requires sustained, multi-site commitment over several years; our digital platform enables this continuity and provides investigators with a continuously expanding dataset for both clinical practice and publication.
Celltrion | YU-MATTER: A Patient’s Experience Switching to a Biosimilar
For Celltrion, the patient-centered e-cohort YU-MATTER assesses patients’ overall satisfaction with Yuflyma (a biosimilar of adalimumab) three months after the first injection, compared to their previous treatment. The adoption of a biosimilar depends as much on patient acceptance as on clinical equivalence, and this acceptance must be measured—it cannot be assumed. The study provides the sponsor with direct, quantified evidence of the patient experience with the switch in IBD and chronic inflammatory rheumatism.
AFPric & Saint-Étienne University Hospital | MethoFolic, a partnership with a rheumatoid arthritis patient organization
Conducted in collaboration with AFPric, the French association for people with polyarthritis, and the Saint-Étienne University Hospital, the MethoFolic study evaluates the experiences of adults treated with methotrexate and folic acid supplementation. Designing a study in collaboration with a patient organization—rather than simply studying patients—changes recruitment, acceptability, and scope; this is what patient-centeredness looks like when it is a working method rather than just a statement.
Lille University Hospital | MentCovRMD, Psychosocial Impact on Patients with Chronic Inflammatory Conditions
MentCovRMD is a RIPH3 cross-sectional observational study conducted in collaboration with the Lille University Hospital, evaluating the sociopsychological consequences of the COVID-19 crisis among patients with chronic rheumatic diseases and systemic autoimmune or autoinflammatory diseases. By combining clinical data and validated mental health indicators in a fully digital study design, it models the effect of systemic shocks on vulnerable populations with chronic conditions, generating actionable evidence for prevention and personalized care.
INSULET | OPTIMAL-A: Real-world evidence from France’s first automated, tubing-free insulin system
The Omnipod 5 automated insulin delivery system was approved by French authorities in January 2024 and has been on the market since June 2024, making it the first tubing-free hybrid closed-loop system available in France. For Insulet, we conducted the OPTIMAL-A study to document the system’s real-world performance. Being first to market means having neither a comparator nor a precedent: evidence must be built from scratch, quickly, and to a standard that satisfies both regulators and payers.
ABBOTT | CETONES-SFDT1, a cross-sectional study in type 1 diabetes
For Abbott Laboratories, as part of the SFDT1 cohort, the CETONES project identifies barriers to self-monitoring of ketones among patients with type 1 diabetes and characterizes the subgroups most likely to be affected. By combining a prospective survey with a retrospective analysis, the study design captures both the lived reality behind low adherence and the clinical evidence that confirms it—this multi-level evidence informs product strategy, patient support programs, and discussions with payers alike.
ARDRM | Metabo-Nutri-COVID, Metabolic Markers, and Prognosis in Acute Care
The Metabo-Nutri-COVID study explores metabolic and nutritional markers as prognostic factors for COVID-19 infections in the context of acute hospitalization. Our teams co-designed the electronic case report form (e-CRF) for data collection and conducted the analysis under the time pressure typical of crisis research: a study that arrives too late is a study that no longer sheds any light on the issue. Delivered within the study window of the fourth quarter of 2020.
Internal Study | Retro-ARV: Ten Years of HIV Care Pathways on the SNDS
Retro-ARV examines the treatment history and care pathways of patients living with HIV in France, identifying changes in therapy over the past ten years and documenting treatment types and durations. By working directly with comprehensive medical and administrative data, the study reconstructs treatment sequences, treatment switches, and treatment persistence in real-world settings across the entire population covered—providing population-level evidence that neither clinical trials nor site-specific registries can produce.
Armed Forces Health Service | Chik: Chikungunya Disease Burden on the SNDS
For the Armed Forces Health Service, this database-driven study (SNDS) describes morbidity, mortality, and healthcare utilization during the period surrounding the chikungunya epidemic in the French West Indies from 2010 to 2019. Conducted in 2019, it is one of the first demonstrations of our capabilities regarding national health databases and confirms that our use of the SNDS is the result of a decade of accumulated methodological expertise, not a recent accreditation.